ISSN ONLINE: 2558-815X
ISSN PRINT: 1584-9244
ISSN-L: 1584-9244

Symptoms Sufficient to Prompt Infliximab-dose Increases in Crohn’s Disease


Dr. Geert D’Haens from Academic Medical Center, in Amsterdam, and colleagues investigated in their study of 122 patients with moderate to severe endoscopically active Crohn’s Disease (CD) if dose increases of Infliximab based on symptoms, biomarkers and/or frequently measured infliximab through level would lead to better outcomes than conventional management based on symptoms alone. The conclusion was that dose increase of infliximab for active CD based on a combination of symptoms, biomarkers, and serum concentrations was not superior to dose increase based on symptoms alone.



Comments are closed.